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Treatment with an antibody targeting CD3 is 
one of the more promising avenues currently 
being pursued for the therapy of organ-specific 
autoimmune diseases. Following the precedents 
from rodent models (Herold et al., 1992; Vallera 
et  al.,  1992;  Hayward  and  Shriber,  1992;   
Chatenoud et al., 1994), administration of anti-
CD3 to patients with recently diagnosed diabe-
tes has yielded favorable results in two clinical 
trials, with a stabilization of disease progression 
(Herold et al., 2002; Keymeulen et al., 2005). 
In both mice and humans, anti-CD3 treatment 
resulted  in  long-lasting  effects  that  persisted 
long after clearance of the antibody. However, 
the  mechanism  of  action  is  not  clear.  TCR 
blockade and internalization, induction of an-
ergy,  and  perturbation  of  the  T  helper  (Th)   
1/Th2 balance have all been invoked (Hayward 
and Shriber, 1992; Alegre et al., 1995; Smith   
et al., 1997). Some studies have suggested an im-
portant role for immunosuppression by TGF, 
although conflicting cytokine sources have been 
proposed (Belghith et al., 2003; Chen et al., 
2008; Perruche et al., 2008). More recently, 
several investigators have suggested that anti-
CD3 therapy may elicit an increase in cells with 
immunoregulatory  properties,  in  particular 
Foxp3+ regulatory T (T reg) cells of the CD4+ 
(You et al., 2007) or CD8+ (Ablamunits and 
Herold, 2008) lineages.
Foxp3+ T reg cells are the best character-
ized lymphocyte subset with a regulatory phe-
notype, playing an important role in the control 
of antiinfectious, antitumor, and autoimmune 
responses (Belkaid and Rouse, 2005; Roncarolo 
and  Battaglia,  2007;  Dougan  and  Dranoff, 
2009). These regulatory activities are mani-
fest via one or more molecular mechanisms 
(Vignali et al., 2008). The homeostasis of T reg 
populations is critical to their potency, but   
is  poorly  understood.  Although  cytokines 
whose receptors use the common  chain (c), 
as well as other molecules, have been shown to 
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Treatment with anti-CD3 is a promising therapeutic approach for autoimmune diabetes, 
but its mechanism of action remains unclear. Foxp3+ regulatory T (T reg) cells may be 
involved, but the evidence has been conflicting. We investigated this issue in mice derived 
from the NOD model, which were engineered so that T reg populations were perturbed, or 
could be manipulated by acute ablation or transfer. The data highlighted the involvement 
of Foxp3+ cells in anti-CD3 action. Rather than a generic influence on all T reg cells, the 
therapeutic effect seemed to involve an 50–60-fold expansion of previously constrained 
T reg cell populations; this expansion occurred not through conversion from Foxp3−  
conventional T (T conv) cells, but from a proliferative expansion. We found that T reg cells 
are normally constrained by TCR-specific niches in secondary lymphoid organs, and that 
intraclonal competition restrains their possibility for conversion and expansion in the spleen 
and lymph nodes, much as niche competition limits their selection in the thymus. The 
strong perturbations induced by anti-CD3 overcame these niche limitations, in a process 
dependent on receptors for interleukin-2 (IL-2) and IL-7.
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17 d of age for BR mice). Diabetes was delayed for a short 
period in the anti-CD3–treated BDC2.5.Foxp3sf mice (Fig. 1 A), 
but no lasting protection was established, and diabetes ap-
peared essentially in sync with waning of the CD3 blockade 
on conventional T (T conv) cells (Fig. 1 B). This result estab-
lished that anti-CD3 could inhibit -cell destruction for the 
short term by blocking T conv cells directly, not through   
T reg cells.
Anti-CD3–treated BR mice were also protected from di-
abetes development but, in contrast, disease blockade lasted 
for a longer time in half of them, reminiscent of the protec-
tion afforded in recently diagnosed diabetic NOD mice: 50% 
of anti-CD3–treated BR mice remained normoglycemic to 
at least 80 d of age (Fig. 1 C). This long-term protection was 
unexpected because BR mice were thought to be devoid of 
T reg cells, as are other MHC-II–restricted TCR transgenic 
mice on a RAG-deficient background (Jordan et al., 2001; 
Knoechel et al., 2005). To more directly tackle the role of   
influence the number of peripheral T reg cells, several issues 
remain unclear: e.g., whether these elements are required 
purely for peripheral homeostasis or are also involved in thy-
mic differentiation of T reg cells; whether they are involved 
in proliferation and/or survival; or whether they are impli-
cated only under specific conditions, such as lymphopenia 
or inflammation.
Some studies on anti–CD3-treated mice have variably 
shown modifications of T reg cells, sometimes present but 
quantitatively modest (Belghith et al., 2003; Bresson et al., 
2006), sometimes absent (Chen et al., 2008), sometimes re-
stricted  to  particular  anatomical  locations  (Belghith  et  al., 
2003; Kohm et al., 2005) or involving cells of an unusual 
CD25low phenotype (You et al., 2007). Certain of the dispa-
rate results may have stemmed from the use of CD25 for the 
identification of T reg cells. This is an issue because NOD 
mice have an unusually high proportion of the CD25-negative 
T reg component (Feuerer et al., 2007), which in most other 
strains constitutes only a minority of Foxp3+ cells (Fontenot 
et al., 2005b).
In this context, we thought it worthwhile to reexamine 
the impact of anti-CD3 treatment on Foxp3+ T reg cells,   
using some powerful new reagents: mice genetically devoid 
of T reg cells, mice in which T reg cells can be acutely ab-
lated, and mice in which T reg cell detection is facilitated by 
fluorescent reporters. The results point in an unexpected di-
rection: anti-CD3 appeared to act by lifting niche limitations 
on the size (and activity) of particular T reg cell clonotypes, 
through a striking and selective burst of amplification.
RESULTS
Anti-CD3 treatment prevented diabetes development  
in BDC2.5.RAGo/o mice
There have been conflicting reports on the importance of   
T reg cells in anti-CD3–induced reversal of diabetes (Belghith   
et al., 2003; Bresson et al., 2006; Chen et al., 2008). We thus 
revisited this issue by evaluating the effect of anti-CD3 treat-
ment in two T reg-deficient diabetes-prone strains of mice. 
Both strains carry the BDC2.5 transgenes (Katz et al., 1993), 
which encode the two chains of a diabetogenic TCR reac-
tive against a  cell antigen. Diabetes in BDC2.5 mice on the 
NOD genetic background is highly regulated, such that ani-
mals present with a restrained insulitis that seldom progresses 
to clinical diabetes, except when also harboring mutations 
leading to a deficiency in CD4+Foxp3+ T reg cells (Lühder   
et al., 1998; Chen et al., 2005). BDC2.5.Foxp3sf mice carry 
the inactivating scurfy mutation at the Foxp3 locus, prevent-
ing effective maturation and survival of T reg cells; and 
BDC2.5.RAGo/o (BR) mice are unable to rearrange endoge-
nous TCR genes and appear as a consequence to be devoid 
of T reg cells. Both of these strains present with very aggres-
sive diabetes, which ensues rapidly after the onset of  cell–
derived antigen presentation in the pancreas-draining lymph 
nodes (PLNs). Mice of the two strains were treated with anti-
CD3 or control antibody in the few days around the onset of 
diabetes (from 12 d of age for BDC2.5.Foxp3sf mice and from 
Figure 1.  Anti-CD3 treatment in T reg-deficient diabetic mice.  
(A and B) BDC2.5.Foxp3sf mice treated with anti-CD3 mAb or control Rat 
IgG from 12 d of age onwards. (A) Diabetes progression (anti-CD3 mAb,  
n = 6; Rat IgG, n = 4). (B) Surface expression of CD3 and BDC2.5 clono-
type TCR on CD4+ cells from spleens. Two to three mice were analyzed at 
each time point. (C) Diabetes progression in BR mice treated with anti-CD3  
(n = 12), PBS (n = 5), or control Rat IgG (n = 7). (D) Diabetes incidence in 
BR.Foxp3DTR+ mice (n = 5) or DTR littermate mice (n = 4) treated with 
anti-CD3 as above. Ablation of T reg cells was provoked by administration 
of DT at 31, 32, 34, 36, and 38 d of age. Individual arrows indicate each 
injection of anti-CD3 mAb or control antibody. (E) Splenic CD4+ cells from 
BR mice 6 d after treatment with anti-CD3 or Rat IgG were analyzed by 
flow cytometry. Numbers indicate the percentage of Foxp3+ cells among 
CD4+ cells. The cytograms are representative of four mice per group.JEM VOL. 207, August 30, 2010 
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T reg cells, we took advantage of BDC2.5.Foxp3DTR mice, 
which express the diphtheria toxin (DT) receptor (DTR) 
under the control of the Foxp3 promoter, and allow T reg 
lineage ablation by administration of DT (Feuerer et al., 
2009). We generated BR.Foxp3DTR mice (hereafter BR.
Foxp3DTR), and young BR.Foxp3DTR+ or BR.Foxp3DTR 
littermates were treated with anti-CD3, followed by DT. All 
the anti-CD3–treated BR.Foxp3DTR+ mice developed diabe-
tes within 5 d of DT treatment, but their transgene-negative 
BR.Foxp3DTR littermates remained protected (Fig. 1 D), 
confirming that Foxp3+ T reg cells are required for long-
term protection. This paradoxical role of Foxp3+ T reg cells, 
in BR mice from which they were thought absent, prompted 
us to analyze protected BR mice by flow cytometry. Quite 
surprisingly, anti-CD3 elicited a very sizeable population of 
Foxp3+CD25+ T reg cells in BR mice (Fig. 1 E).
A dramatic expansion of T reg cells in anti-CD3– 
treated BR mice
We next investigated in more detail the kinetics and distribu-
tion of the surprising population of Foxp3+ cells elicited by 
anti-CD3 in BR mice. The appearance of T reg cells was 
systemic, observed in all secondary lymphoid organs, al-
though the expression of CD25 differed in the spleen and 
subcutaneous LN, relative to pancreas- and gut-associated 
LNs (Fig. 2 A). Interestingly, the intensity of CD25 expres-
sion initially varied with anatomical location, high in spleen 
and ILN, lower in MLN or PLN, which one might speculate 
stems from a different amount of IL-2 in these locations   
(Fig. 2 B). These varying levels normalized at later times. The 
Foxp3+ population appeared rapidly upon administration of 
anti-CD3, with a maximum at day 6–9 after treatment for 
both their proportion among CD4+ T cells (Fig. 2 C) and 
their  absolute  numbers  (Fig.  2  D).  They  waned  slightly 
thereafter, but persisted in the 2–4% range for a long time. 
Foxp3+ cells were observed in the infiltrated islets of “cured” 
BR mice, with a scattered disposition reminiscent of that   
of T reg cells in the restrained insulitis of RAG-positive 
Figure 2.  Anti-CD3 induces a burst of T reg cells in BR mice.  
(A) CD4+ cells in the spleen, pancreatic, inguinal, and mesenteric lymph 
node (SPL, PLN, ILN, and MLN, respectively) from mice untreated or 
treated with anti-CD3 or control IgG were analyzed by flow cytometry. 
CD4+ cells in the SPL and PLN from BDC2.5.NOD mice were depicted as 
controls. Numbers indicate the percentage of Foxp3+ cells among CD4+ 
cells. (B) Mean fluorescence intensity of surface CD25 in FoxP3+ cells from 
different lymphoid organs, 6 or 14 d after anti-CD3 treatment. To normal-
ize for experimental variation between experiments, data were normalized 
relative to NOD T reg splenocytes used as a staining control in each  
experiment. (C and D) Percentage and absolute numbers of Foxp3+ CD4+ 
cells in the SPL and PLN of anti-CD3–treated BR mice. (E) Localization of 
Foxp3+ cells in residual pancreatic infiltrates from BR mice before or 21 d 
after treatment with anti-CD3. Data in A–E are representative of three to 
six independent experiments. (F) Expression of T reg signature transcripts 
in CD4+Foxp3+ T reg cells elicited by anti-CD3 in cured BR mice, 11 or 12 d 
after treatment, compared with natural T reg cells from BDC2.5 mice  
(BDC T regs). RMA-normalized expression values from triplicate Affymetrix 
M430v2 microarrays were averaged, standardized relative to expression  
in BDC2.5 T conv cells, and ranked according to differential over- or  
underexpression in natural BDC2.5 T reg cells.
 1882 T reg cell niche reset by anti-CD3 | Nishio et al.
Second, we tested the hypothesis that anti-CD3 induces 
conversion from Foxp3-negative precursors by performing 
cell transfer experiments using Foxp3 donor cells (Fig. 3 C). 
The Foxp3GFP knock-in reporter (Fontenot et al., 2005b) was 
crossed into the BR line, and donor cells were rigorously 
sorted as GFP cells to <0.01% contamination, before trans-
fer into age-matched NOD.CD90.1 congenic hosts (a lympho-
replete host was used to avoid the rapid conversion that 
follows  transfer  into  lymphopenic  hosts;  Lin  et  al.,  2007; 
Lathrop et al., 2008; Leung et al., 2009; Feuerer et al., 2010). 
Hosts were treated the next day with anti-CD3 or control 
mAb, as above, and tested after 6–8 d. Although some degree 
of conversion to GFP+ was observed in GFP cells, it only 
occurred at a low level and was not different in mice treated 
with anti-CD3 or control mAb. These results suggest that the 
BDC2.5 mice (Fig. 2 E); in contrast, large infiltrates devoid 
of Foxp3+ cells were found throughout the pancreas of con-
trol BR mice.
The intensity of Foxp3 in these anti-CD3–elicited cells 
was comparable with those of bona fide T regs (Figs. 1, 2). 
To further characterize these cells, we determined gene- 
expression profiles of sorted CD4+GFP+ cells in Foxp3GFP 
knock-in reporter (Fontenot et al., 2005b; R Foxp3GFP) mice, 
10 d after anti-CD3 treatment (in triplicate on Affymetrix 
M430 arrays). These were compared with profiles deter-
mined in parallel from normal T reg and T conv cells of 
BDC2.5.RAG+ mice, used here as a reference for unmanip-
ulated T reg cells. The plot of Fig. 2 F depicts the expression 
levels  (relative  to  T  conv)  of  transcripts  differentially  ex-
pressed in T reg cells (ranked according to T reg/T conv cell 
ratios, and focusing on the extremes of the T reg/T conv cell 
differential). The Foxp3+ T cells induced in anti-CD3–treated 
BR mice were very similar to T reg cells from BDC2.5 mice, 
with differential expression of the usual set of diagnostic 
genes: overexpression of Foxp3, Il2ra, Ikzf2, Nrp1, etc., 
and underexpression of Pdlim4, Pde3b, etc. Rare T reg cell 
signature transcripts stood out as even more differentially ex-
pressed in anti-CD3–elicited Foxp3+ cells, relative to BDC2.5 
T reg cells (e.g., Igfbp4, Rapgef, or even FoxP3 itself), a few 
others less so (e.g., Gpr15, Cd38, or Socs2). We also noted 
relatively high expression of Itgae (CD103) and Klrg1, mark-
ers of a particular T reg cell subpopulation (Stephens et al., 
2007; Beyersdorf et al., 2007; Feuerer et al., 2010). Overall, 
the cells elicited by anti-CD3 of BR mice seemed like bona 
fide T reg cells, in terms of anatomical location and genome-
wide phenotype.
Origin of T reg cells in anti-CD3–treated BR mice
The sudden appearance of the Foxp3+CD4+ T reg cell popu-
lation begged the question of its origin. Theoretically, these 
cells could originate from the thymus, a plausible scenario 
given the precedent of agonist-driven T reg cell selection 
(Jordan et al., 2001). Alternatively, they might be of periph-
eral origin, resulting either from conversion of T conv cells 
to a Foxp3+ phenotype or from amplification of a preexisting 
pool of very rare T reg cells (Kretschmer et al., 2005).
Several experiments ruled out a required impact of anti-
CD3 in the thymus. First, although Foxp3+ cells did appear 
in the thymus after anti-CD3 treatment of BR mice (Fig. 3 A), 
their proportion was comparatively low (only 2% of mature 
CD4+CD8 thymocytes). In addition, the timing of their 
induction was largely superimposable to that of peripheral 
Foxp3+ cells, rendering a precursor–product relationship 
rather  unlikely.  More  definitively,  BR  mice  thymecto-
mized 1 d before anti-CD3 administration exhibited the 
characteristic induction of Foxp3+CD4+ cells in peripheral 
lymphoid organs, which was only marginally less than that 
of sham-operated BR mice (Fig. 3 B). Thus, the thymus is 
dispensable during the period of exposure to anti-CD3, 
and the new population of T reg cells must have a periph-
eral origin.
Figure 3.  Origin of T reg cells in anti-CD3–treated BR mice.  
(A) Percentage and absolute numbers of Foxp3+ CD8CD4+ cells in the 
thymus of anti-CD3–treated BR mice. Data are pooled from 3–6 mice per 
each time point. (B) Percentage of Foxp3+ cells in CD4+ cells in BR mice 
that were thymectomized or sham-operated before anti-CD3 treatment  
(n = 3 per each group). (C) GFP cells from 15-d-old BR.Foxp3GFP mice were 
transferred into age-matched CD90.1.NOD hosts, anti-CD3 treatment 
being initiated 24 h after transfer. Six to eight days later, CD4+ T cells 
from SPL and PLN were analyzed by flow cytometry. Representative flow 
cytograms are shown at left, and pooled data from four experiments are 
combined (right).JEM VOL. 207, August 30, 2010 
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These appeared to be true T reg cells, expressing Foxp3 and 
the usual level of CD25 (Fig. 2). Although this finding was 
unexpected, as it is usually assumed that TCR transgenic 
mice on a RAG-deficient background are devoid of T reg 
cells, it was consistent with very recent studies that very small 
T reg compartments are selected in the thymus of monoclonal 
TCR transgenic mice such as BR, but that intraclonal com-
petition between immature thymocytes expressing the same 
TCR specificity drastically limits the number of selected cells 
(Bautista et al., 2009; Leung et al., 2009).
Next, we asked whether anti-CD3 might provoke the 
proliferation of these rare preexisting T reg cells. BR mice re-
ceived a 6-h pulse of BrdU at different times after anti-CD3 
treatment, and incorporation of the label was evaluated by 
flow cytometry (Fig. 4, B and C). Both T reg and T conv cells 
proliferated rapidly in the first day after anti-CD3 treatment, 
but T reg cells continued to expand 
further, with up to 40% of T reg cells 
actively cycling a few days after treat-
ment, whereas the expansion of T conv 
cells subsided quickly after the first day. 
These differential rates of cell division 
can certainly account for the expansion 
of T reg cells from the initial 0.25% to 
the 5–8% observed 6 d later. The pro-
portion of BrdU-labeled cells suggests 
sudden appearance of the T reg cell population after anti-
CD3 treatment of BR mice does not result from conversion 
of T conv cells. Another caveat was that these Foxp3+ cells 
arise not as a consequence of anti-CD3 itself, but from the 
large amounts of antigen released at onset of diabetes, which 
could promote agonist-induced conversion. This caveat was 
tested by analyzing BR mice maintained after onset of diabe-
tes with insulin pellet; in this case, no increase in T reg cells 
was observed (Fig. S1).
We then weighed the hypothesis of a rapid amplification 
of a rare population of T reg cells preexisting in BR mice. 
Upon close examination of their secondary lymphoid organs, 
with carefully controlled anti-Foxp3 staining or with BR.
Foxp3GFP reporter mice, a small but distinct population of   
T reg cells was detected, representing 0.15–0.25% of splenic 
CD4+ T cells (over backgrounds of 0.03–0.05%; Fig. 4 A). 
Figure 4.  Specific proliferative expansion 
of T reg cells in anti-CD3–treated BR 
mice. (A) Anti-Foxp3 or isotype-matched 
control staining of splenic CD4+ cells from an 
untreated BR mouse at 17 d of age (top); GFP 
expression in CD4+ cells from untreated BR.
Foxp3GFP mouse (bottom). Note that 10-fold 
more cells were collected than in previous 
figures. Numeric data from three mice are 
shown in the histogram at right. (B) BrdU 
incorporation by T reg and T conv cell CD4+ 
splenocytes in BR mice during a 6-h pulse, 
before or at 3, 6, or 9 d of anti-CD3 treat-
ment. The numbers indicate the percentage of 
BrdU+ cells in Foxp3+ or Foxp3 CD4+ cells. 
The flow cytograms were representative from 
three mice per time point. (C) Kinetics of the 
proportion of BrdU+ cells in T reg cells and  
T conv cells, compiled from several experi-
ments as shown in B. Dots represent mean ± 
SD of two to five mice per time point.  
(D and E) Proportion and absolute numbers  
of CD4+Foxp3+ cells in CD4+ cells from the 
spleens and PLNs of NOD mice recently diag-
nosed as diabetic (recent DM), before or after 
treatment with anti-CD3. (F) Proportion of 
BrdU+ cells among T reg and T conv SPL cells 
of NOD mice, in prediabetic state (preDM), 
recent DM, and 3 or 6 d of anti-CD3 treat-
ment (6-h pulse as above). Dots represent 
mean ± SD of three mice per time point.1884 T reg cell niche reset by anti-CD3 | Nishio et al.
in only background 
levels of GFP+ cells 
in  the  same  hosts. 
Both types of donor 
cells were able to 
generate Foxp3+ cells upon transfer into an empty NOD.
RAGo/o host (Fig. 5, right). These results suggest that the 
BDC2.5 transgenic hosts, although they do harbor T reg 
cells, offer several T reg niches for cells displaying TCR spec-
ificities different from their own.
The newly generated Foxp3+ cells were very stable, per-
sisting at the same levels for several months, and also remained 
Foxp3+ through serial retransfer (Fig. S2). They expressed 
several transcripts typical of the T reg cell signature (unpub-
lished data), and were fully functional, protecting from diabe-
tes in a transfer assay (Fig. 5 B).
If this conversion and expansion of T reg cells were in re-
sponse to TCR-specific niches left unoccupied in the hosts, 
one should be able to visualize the specificity and size vari-
ability of these niches as an imprint on the expanded reper-
toire. We have previously shown that T reg and T conv cells 
in BDC2.5 mice express endogenous TCR genes, whose 
products pair with the transgene-encoded TCR chain; this 
diversity allows for selection of a far more robust T reg cell 
compartment than that of BR mice. Different motifs of rear-
ranged CDR3 segments are used in T reg and T conv cells, 
which provide a useful “tag” for fate-mapping (Wong et al., 
2007). The sequence of TCR chains expressed by single 
Foxp3+ cells found 14 d after transfer into NOD.RAGo/o 
hosts were determined. Fig. 6 A summarizes data from 174 
converted Foxp3+ cells, and 165 Foxp3 nonconverted cells, 
from two independent donor mice (all sequences are tabu-
lated in Table S1). The CDR3 sequences found in these 
converted and expanded T reg cells were diverse (Fig. 6 A, 
left). They included sequences normally found in the T conv 
repertoire (as expected from the conversion event), but also 
some sequences normally found in T reg cells (perhaps origi-
nating from expansion of rare contaminating T reg cells in 
the donor pool). Importantly, however, the relative distribu-
tion of sequences was different from that of either T reg or   
T conv cells from BDC2.5 mice, indicating that the homeo-
static pressure to fill the niches led to a reordering of sequence 
frequencies. This point is made most explicit in Fig. 6 B, 
which compares the frequency of CDR3 sequences in   
T conv cells that became Foxp3+ versus those that remained 
Foxp3-negative (focusing on sequences of T conv origin). 
Very different representations were found in the two groups 
a population average division time of 10 h, or 8–10 divisions 
over the 4-d period, potentially leading to a 210 expansion of   
T reg cell numbers. Thus, anti-CD3 treatment results in a dra-
matic expansion of these monoclonal T reg cells.
We then asked whether this explosive amplification was 
particular to the rare T reg cells of BR mice, or whether it 
was a more general phenomenon. NOD mice recently diag-
nosed with diabetes were treated with anti-CD3 according to 
the same regimen. Consistent with previous reports, diabetes 
reverted in 15 of 37 mice treated (unpublished data). Pro-
tected  animals  showed  an  increase  in  the  proportions  of 
Foxp3+ T reg cells, though the changes in numbers were less 
clear (Fig. 4, D and E). In keeping with observations in BR 
mice, cell cycling was observed in both T reg and T conv, 
again, preferentially in T reg cells (Fig. 4 F).
TCR-specific niches in peripheral lymphoid organs
Thus, anti-CD3 treatment appeared to unleash the expansion 
of a monoclonal population of T reg cells, normally selected 
and maintained at low frequency. Yet, strong homeostatic 
pressure on T reg cell pools is able to drive the conversion of 
Foxp3− T conv cells and their expansion to restore peripheral 
T reg cell pools (Liang et al., 2005; Lin et al., 2007; Feuerer 
et al., 2010), to a level determined at least in part by dendritic 
cells (Darrasse-Jèze et al., 2009). If so, why do the rare T reg 
cells of BR mice (or other such monoclonal TCR mice) not 
expand to fill the peripheral pools? One hypothesis is that   
T reg cells of a given specificity can only occupy a niche of 
restricted size in the periphery.
We tested this hypothesis in a series of transfer experi-
ments, using as donors Foxp3-negative CD4+ cells displaying 
different TCRs (polyclonal NOD or restricted BDC2.5) 
identifiable  with  a  CD90.1  congenic  marker.  These  cells 
were rigorously sorted on the basis of a Foxp3GFP marker, and 
were transferred into hosts in which T reg cell pools were 
themselves  polyclonal,  restricted,  or  completely  missing 
(NOD,  BDC2.5,  or  NOD.RAGo/o  hosts,  respectively). 
There  was  little,  if  any,  conversion  of  T  conv  cells  into 
Foxp3+ T reg cells from polyclonal NOD donors upon trans-
fer into NOD hosts,. This was expected, as transfer of poly-
clonal cells into lympho-replete hosts is known to elicit little 
or no conversion. In contrast, the introduction of the same 
NOD T cells into restricted-repertoire BDC2.5 hosts yielded 
a robust population of Foxp3+ cells (Fig. 5 A, middle). This 
behavior did not reflect a generic propensity of BDC2.5 hosts 
to support T reg conversion and expansion, because transfer 
of CD4+ T conv cells from BDC2.5.Foxp3GFP mice resulted 
Figure 5.  TCR-specific niches in periph-
eral lymphoid organs. (A) Flow-sorted 
CD4+GFP cells from TCR-transgenic BDC2.5+.
CD90.1.Foxp3GFP (BDC) or CD90.1.Foxp3GFP 
(NOD) donors (<0.1% GFP+) were transferred 
to NOD, BDC2.5, or NOD.RAGo/o hosts, and the 
proportion of GFP+ cells was measured after 
14 d. (B) Diabetes in NOD.RAGo/o recipients of 
5 × 104 naive BDC2.5 T cells (effector), alone 
or with 2.5 × 104 cells recovered from transfer 
experiments as in A (BDC2.5.CD90.1 either 
GFP+ converted or GFP nonconverted). Four 
mice per group.JEM VOL. 207, August 30, 2010 
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of cells. Similar results were reported by Lathrop et al. 
(Lathrop et al., 2008) who showed, in a different single-chain 
TCR system, that homeostatically driven conversion to 
Foxp3+ phenotype differentially affects cells with different 
TCRs. Thus, the availability of open niches appears to pro-
mote a thorough reordering of TCR frequencies.
Is the size of these niches similar among different organs 
of the same mouse, and are they influenced by the reactivity 
of the BDC2.5 clonotype to its pancreatic antigen? After 
transfer of BDC2.5 T cells into NOD.RAGo/o hosts, Foxp3+ 
cells were found in all secondary lymphoid organs, but most 
prominently in the subcutaneous lymph nodes and spleen, 
rather than in the mesenteric or pancreas-draining lymph 
nodes (Fig. 7, A and B). Similar patterns were found in 
TCRo/o hosts, indicating that T cell lymphopenia alone was 
sufficient to drive the conversion and expansion of Foxp3+ 
cells, irrespective of the B cell pool (Fig. 7 B). A time-course 
Figure 6.  The TCR repertoire influences the ability to homeostati-
cally convert to Foxp3+ BDC2.5.CD90.1. Foxp3GFP+ (converted) and 
Foxp3GFP (not converted) T cells were isolated 14 d after transfer into 
lymphopenic hosts as in Fig. 5 A. V2+ cells were sorted for single-cell 
amplification and sequencing of the CDR3 regions of endogenously 
rearranged TCR loci (used as a lineage-tracing tag, per Wong et al., 
2007). (A) Comparison of the frequencies of CDR3 sequences between 
Foxp3+ and Foxp3 BDC2.5 T cells, displayed as a frequency heat map. 
Sequences were aligned based on their frequencies in converted Foxp3+ 
cells, and compared with the frequencies observed previously in T reg and 
T conv cells from LN and thymus of BDC2.5 mice (data from Wong et al., 
2007). (B) Comparison of the frequencies of CDR3 sequences in trans-
ferred cells, either Foxp3+ converted or nonconverted cells that remained 
Foxp3 (ranked according to frequencies in nonconverted cells). Data 
were pooled from two independent experiments.
Figure 7.  Anatomical location of TCR-specific T reg niches. Cells 
from the SPL, axillary lymph node (AxLN), MLN, and PLN of NOD.RAGo/o 
hosts 14 d after transfer of GFP cells from BDC2.5.CD90.1.Foxp3GFP mice 
were analyzed by flow cytometry. (A) Representative dot plots. Numbers 
indicate the percentage of Foxp3+ cells among CD4+ cells. Plots are gated 
on CD90.1+ T cells. (B) Percentage of Foxp3+ donor cells after transfer of 
BDC2.5 Foxp3 cells into NOD.RAGo/o and TCRCo/o hosts; bars show 
mean ± SD of four mice per group. (C) Time course of the appearance of 
Foxp3+ cells after transfer of BDC2.5 Foxp3 cells into NOD.RAGo/o hosts. 
(D) Percentage of Foxp3+ cells after transfer of NOD Foxp3 cells into 
BDC2.5 hosts; bars show mean ± SD of 4 mice per group.1886 T reg cell niche reset by anti-CD3 | Nishio et al.
niches available to them. These forces are evident after T cell 
transfer into a host in which the niches are empty (e.g., NOD 
T cells into BDC2.5 mice; NOD or BDC2.5 T cells into 
lymphopenic recipients) or when niche limitations are dis-
turbed by extraneous treatment, e.g., administration of anti-
CD3. The divergent responses of donor T cell populations 
expressing different repertoires of TCRs, and the distinct set 
of  TCR  sequences  found  in  converted/amplified  T  reg 
cells, both indicate that peripheral homeostasis of the T reg 
cell pool is set not only at a general population-wide level, 
but also for individual TCRs or families thereof. In this re-
spect, peripheral T reg niches appear to prolong the intra-
clonal  competition  observed  during  their  selection  in  the 
thymus (Bautista et al., 2009; Leung et al., 2009).
Our results suggest that limitations that define T reg cell 
niches are imposed by both TCRs and receptors for trophic 
cytokines,  acting  in  combination.  The  TCR  component, 
manifest as CDR3 sequence specificity, most likely reflects 
competition for specific MHC–peptide ligands presented by 
dendritic cells and/or other lymphoid stromal cells. This in-
terpretation is consistent with the recent report that increas-
ing the pool of DCs also increased T reg cell numbers 
(Darrasse-Jèze et al., 2009). It is possible that these ligands 
represent  a  nonrenewable  resource,  engagement  by  the 
TCRs of one T reg cell leading to their internalization, or to 
stripping of these ligands from the APC surface. Antigen rec-
ognition by T cells has long been known to result in uptake 
of the MHC–peptide complexes by the responding T cell 
(Lorber et al., 1982; Tsang et al., 2003). Alternatively, the 
specific MHC–peptide complexes might control the dwell-
time allowed to T reg cells on APC surfaces, and competition 
may be a form of “crowding out” for access to an otherwise 
stable resource. Whether this TCR-specific limitation repre-
sents a strict intra-lineage competition (T reg cells competing 
among themselves), or an interlineage competition (T conv 
crowding out T reg cells) remains an open question, and it is 
Figure 8.  The appearance of T reg cells after anti-CD3 treatment is dependent on IL-2 and IL-7Ra, but not on TGF. (A) Percentage and ab-
solute numbers of Foxp3+ cells among CD4+ cells from the spleen of o BR mice 6 d after treatment with anti-CD3, in combination with anti-TGF (2G7) or 
with control antibody (rat IgG). Antibodies were injected i.p. every other day, starting from the day of anti-CD3 initiation. (B) Percentage and absolute 
numbers of Foxp3+ cells among CD4+ cells from the spleen of BR mice 8 d after treatment with anti-CD3 in combination with neutralizing anti-IL-2, anti-
IL-7R, anti-IL-15, or control IgG. 75 µg of each neutralizing mAb was injected i.p. for 6 consecutive days, starting from the day of anti-CD3 initiation.  
(A and B) Bars represent mean ± SD of three to four mice per group. (C) IL-2–anti–IL-2 complexes were administered to BR mice for 5 consecutive days 
from 17 d of age. Cells from SPL and PLN were analyzed by flow cytometry. The cytograms are representative of two to three mice per group.
experiment showed equally low percentages of T reg cells in 
all the organs at days 4 and 7 after transfer, with a rapid in-
crease in the second week after transfer (Fig. 7 C). An equally 
broad distribution of Foxp3+ cells was also observed after 
transfer of NOD T conv cells into BDC2.5 hosts (Fig. 7 D). 
Thus, niche-filling conversion and amplification are not re-
lated to the potential autoreactivity of the TCR.
Cytokine involvement in overcoming T reg niche limitations
For T conv cells, homeostatic control is maintained by the 
existence of TCR-dependent niches, and by limiting trophic 
cytokines such as IL-7 and IL-15 (Surh and Sprent, 2008; 
Rochman et al., 2009). We asked which cytokines might be 
involved in the anti-CD3–mediated surmounting of TCR-
specific niche size in BR mice, testing those cytokines known 
to partake in thymic differentiation of T reg cells and/or their 
peripheral  survival.  Co-treatment  of  antibodies  targeting 
TGF (mAb 2G7), along with anti-CD3, showed that this 
cytokine was not involved, the usual induction of Foxp3+ 
cells being observed in the spleen and PLN (Fig. 8 A).   
In  contrast,  coadministration  of  anti–IL-2  or  anti–IL-7R 
with anti-CD3 strongly reduced the yield of Foxp3+ cells, al-
though not quite to the level of controls not receiving anti-
CD3 (combination of the two anti-cytokine antibodies had a 
similar effect; unpublished data). Anti–IL-15, on the other 
hand, seemed to have no influence. Thus, both IL-2 and IL-7 
(or thymic stromal lymphopoietin [TSLP]), which also acti-
vates IL-7R) seem to be required for niche resetting. The 
relevance of IL-2 was confirmed by treating BR mice with 
IL-2–anti–IL-2 complexes (Boyman et al., 2006), which re-
sulted in a strong expansion of Foxp3+ cells (Fig. 8 C).
DISCUSSION
In this study, two quite different lines of experimentation 
converged to illustrate the strong forces driving T reg cells, 
through conversion and/or amplification, to fill the restricted JEM VOL. 207, August 30, 2010 
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IL-2/anti–IL-2 complexes largely mimicked the expansion 
of T reg cells, but the brutal jolt given to T reg cells by anti-
CD3 may also promote their expansion.  Particularly  in-
triguing was the observation that T reg cells proliferated 
significantly more than T conv cells in treated BR mice.   
In polyclonal NOD mice, the same proliferative advantage 
was observed for T reg cells, albeit numerically more muted; 
this might suggest that the changes elicited by anti-CD3, 
which are long-lasting in their protective effect, include a re-
assortment of the T reg repertoire, with relative amplification 
of previously limited specificities.
Our findings have several implications for anti-CD3 ther-
apy of autoimmune and other diseases. The KT3 mAb we 
used, although relatively nontoxic and capable of inducing 
only a limited “cytokine storm” (Mottram et al., 2002), may 
have more cytokine-inducing capacity than some of the Fab 
or non–Fc-binding molecules used in the clinic. Preliminary 
studies with an F(ab’)2 preparation of the 2C11 mAb injected 
into BR mice also showed an expansion of the T reg cell 
pool, but somewhat delayed, peaking at day 14 (unpublished 
data). It may thus be desirable to test in humanized mouse 
models the true impact of the preparations used in patients. 
Our data suggest that a transient therapeutic effect of anti-
CD3 treatment might be obtained from the TCR blockade/
internalization component, as deduced from the results in 
BDC2.5.Foxp3sf mice; although short-lived, this effect might 
be desirable in limiting acute damage in rapidly evolving dis-
ease in some patients. A reassortment of the T reg cell reper-
toires would then ensue, and our data would suggest that the 
production of IL-2 elicited by these reagents as part of the 
cytokine storm response, as well as a differential sensitivity, 
may actually be important contributing elements in the ther-
apeutic effect, via resetting of the T reg niches.
MATERIALS AND METHODS
Mice. BR, BDC2.5.Foxp3sf, Foxp3GFPNOD, and BDC2.5.Foxp3DTR used 
for intercrosses (all on the NOD/LtJDoi background) have been previously 
described (Gonzalez et al., 2001; Chen et al., 2005; Feuerer et al., 2009). All 
were maintained in specific pathogen–free facilities at the Joslin Diabetes 
Center and Harvard Medical School (IACUC 99–20, 02954).
For anti-CD3 treatment, mice were injected i.v. with 3 µg/g BW of anti-
CD3 mAb (clone; KT3; protein G purified) for 5 consecutive days. For T reg 
depletion in BR.Foxp3DTR mice, 50 µg/g BW of DT was administered at days 
1, 2, 4, 6, and 8). For blocking studies, 75 µg of anti–IL-2 (clone; JES6-1A12; 
BioLegend), anti–IL-7Ra (clone; A7.R34.2.2; protein G purified), and anti– 
IL-15 (clone; AIO.3; eBioscience) were injected ip for 6 consecutive days, start-
ing on the same day as anti-CD3. 0.5 mg of anti-TGF (clone; 2G7; protein   
G purified) was administered every other day for 2 wk. For in vivo BrdU incor-
poration, 0.01 mg/g BW of BrdU was injected i.p., 6 h before euthanasia.
Animals were monitored for glycemic control (glycosuria), with confir-
mation by blood glucose measurements, and mice were considered diabetic 
if blood glucose levels were >350 mg/dl on two consecutive draws.
Flow Cytometry. Cell surface staining was performed per standard proce-
dures and reagents. Intracellular staining for Foxp3 and BrdU staining was 
performed with manufacturer’s protocols (clone FJK-16s; eBioscience; BrdU 
Flow kit; BD). For costaining of Foxp3 and BrdU, BrdU staining was per-
formed after Foxp3 staining. Analysis was performed using LSRII instrument 
(BD) and FlowJo software (Tree Star, Inc.).
interesting to note that clonotypic limitations on selection of 
T reg cells in the thymus have similarly been proposed to re-
flect T reg/T conv cell (van Santen et al., 2004) or intraclonal 
T reg/T reg cell competition (Bautista et al., 2009). The cy-
tokine element is represented by IL-2 and IL-7 (or TSLP), 
consistent with the impact of a deficiency in their receptors 
on T reg cell homeostasis (Fontenot et al., 2005a; Yao et al., 
2006; Bayer et al., 2008). It is not clear from our data whether 
these cytokines exert complementary effects after anti-CD3 
treatment or are merely additive and partially redundant.   
A limiting supply of cytokines might combine with limiting 
TCR ligands, for example if a focused delivery of trophic cy-
tokines by the APC is initiated by a productive TCR/MHC–
peptide engagement, or if TCR signals sensitize the T reg cell   
to being receptive to cytokine signals (most simply, by main-
taining surface IL-2R or IL-7R levels).
In several respects, the peripheral niche limitations seem to 
represent a continuation of the intraclonal competition for   
commitment to the T reg cell lineage observed in the thymus   
(Bautista et al., 2009; Leung et al., 2009). In particular, the com-
bination of TCR and IL-2R signals is of central importance in 
T reg cell differentiation and selection in the thymus. As had 
been speculated for homeostatic control of T conv cells, the 
peptides that elicit positive selection in the thymus may be the 
same as those conditioning peripheral survival and niche size.
There are clear parallels between the niche limitations on 
T reg cells and the homeostatic control of naive T conv cells, 
whose survival and homeostatically driven proliferation in 
the periphery are also dependent on continued TCR “tick-
ling” and cytokines (Surh and Sprent, 2008). The niche sizes 
are different there being far more T conv than T reg cells in 
monoclonal TCR-transgenic RAGo/o mice, and the required 
cytokines are different (there being less of a role for IL-2 in   
T conv cell homeostasis, although IL-7 influences both; Surh 
and Sprent, 2008; Rochman et al., 2009; Ma et al., 2006). 
But the operating principles are basically the same. In both 
cases, setting homeostatic controls linked to individual TCR 
specificities, rather than operating only at the overall popula-
tion level, would be an important element to maintain a 
broad repertoire and avoid takeover by individual clones.   
Interestingly, though, T reg cells have been shown to influ-
ence homeostatic controls on T conv populations (Murakami 
et al., 2002; Barthlott et al., 2003), and it is also possible that 
T conv populations play a role in modulating T reg cell   
homeostasis (although it is easier to imagine generic control 
rather than TCR-specific niche control).
What happens after anti-CD3 therapy? Perhaps surpris-
ingly, the T reg cells amplified in BR mice seemed quite 
similar to normal T reg cells from BDC2.5 mice, in transcrip-
tional phenotype. It is plausible that anti-CD3 treatment breaks 
through the niche ceiling due to a combination of strong TCR- 
and cytokine-receptor-mediated signals. By analogy, both 
TCR and cytokine signals are necessary for homeostatic ex-
pansion of T conv cells in lymphopenic hosts (Surh and Sprent, 
2008; Rochman et al., 2009). Cytokine receptor signals could 
explain much of the response, given that administration of 1888 T reg cell niche reset by anti-CD3 | Nishio et al.
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